chr3-128485892-T-C
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_032638.5(GATA2):āc.706A>Gā(p.Met236Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000192 in 1,613,934 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.000026 ( 0 hom., cov: 32)
Exomes š: 0.000018 ( 0 hom. )
Consequence
GATA2
NM_032638.5 missense
NM_032638.5 missense
Scores
3
5
11
Clinical Significance
Conservation
PhyloP100: 5.81
Genes affected
GATA2 (HGNC:4171): (GATA binding protein 2) This gene encodes a member of the GATA family of zinc-finger transcription factors that are named for the consensus nucleotide sequence they bind in the promoter regions of target genes. The encoded protein plays an essential role in regulating transcription of genes involved in the development and proliferation of hematopoietic and endocrine cell lineages. Alternative splicing results in multiple transcript variants.[provided by RefSeq, Mar 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High AC in GnomAdExome4 at 27 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GATA2 | NM_032638.5 | c.706A>G | p.Met236Val | missense_variant | 3/6 | ENST00000341105.7 | NP_116027.2 | |
GATA2 | NM_001145661.2 | c.706A>G | p.Met236Val | missense_variant | 4/7 | NP_001139133.1 | ||
GATA2 | NM_001145662.1 | c.706A>G | p.Met236Val | missense_variant | 3/6 | NP_001139134.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GATA2 | ENST00000341105.7 | c.706A>G | p.Met236Val | missense_variant | 3/6 | 1 | NM_032638.5 | ENSP00000345681.2 | ||
GATA2 | ENST00000487848.6 | c.706A>G | p.Met236Val | missense_variant | 4/7 | 1 | ENSP00000417074.1 | |||
GATA2 | ENST00000430265.6 | c.706A>G | p.Met236Val | missense_variant | 3/6 | 1 | ENSP00000400259.2 | |||
GATA2 | ENST00000696466.1 | c.988A>G | p.Met330Val | missense_variant | 5/8 | ENSP00000512647.1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152118Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
4
AN:
152118
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 250898Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135746
GnomAD3 exomes
AF:
AC:
5
AN:
250898
Hom.:
AF XY:
AC XY:
2
AN XY:
135746
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000185 AC: 27AN: 1461816Hom.: 0 Cov.: 32 AF XY: 0.0000151 AC XY: 11AN XY: 727200
GnomAD4 exome
AF:
AC:
27
AN:
1461816
Hom.:
Cov.:
32
AF XY:
AC XY:
11
AN XY:
727200
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152118Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74298
GnomAD4 genome
AF:
AC:
4
AN:
152118
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74298
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:5Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 10, 2023 | Observed in large population cohorts (gnomAD; internal data); In silico analysis supports that this missense variant does not alter protein structure/function; Observed in an individual with pancytopenia, lymphadenopathy, and splenomegaly (PMID: 31309983); This variant is associated with the following publications: (PMID: 31309983) - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2024 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Dec 17, 2019 | This sequence change does not appear to have been previously described in patients with GATA2-related disorders and has been described in the gnomAD database with a low population frequency of 0.0080% in African subpopulation (dbSNP rs746737860). The p.Met236Val change affects a moderately conserved amino acid residue located in a domain of the GATA2 protein that is known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Met236Val substitution. Due to these evidences and the lack of functional studies, the clinical significance of the p.Met236Val change remains unknown at this time. - |
Monocytopenia with susceptibility to infections Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Jul 17, 2019 | This GATA2 variant (rs746737860) is rare (<0.1%) in large population datasets (gnomAD: 6/82258 total alleles; 0.002126%; no homozygotes). This variant is not described in the literature to our knowledge, and a single submitter in ClinVar classifies the sigificance of this variant as uncertain. Two bioinformatic tools queriedpredict that this substitution would be tolerated, however the methionine residue at this position is evolutionarily conserved across all species assessed. Bioinformatic analysis predicts that this missense variant would not affect normal exon 3 splicing, although this has not been confirmed experimentally to our knowledge. The clinical significance of c.706A>G is uncertain at this time. - |
Acute myeloid leukemia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 10, 2024 | - - |
Deafness-lymphedema-leukemia syndrome;C3280030:Monocytopenia with susceptibility to infections Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 06, 2023 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Benign
DANN
Benign
DEOGEN2
Benign
T;.;T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Benign
.;T;T
M_CAP
Uncertain
D
MetaRNN
Uncertain
D;D;D
MetaSVM
Uncertain
D
MutationAssessor
Benign
L;L;L
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;N
REVEL
Uncertain
Sift
Benign
T;T;T
Sift4G
Benign
T;T;T
Polyphen
B;B;B
Vest4
MutPred
Loss of glycosylation at T235 (P = 0.0142);Loss of glycosylation at T235 (P = 0.0142);Loss of glycosylation at T235 (P = 0.0142);
MVP
MPC
ClinPred
T
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at